Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma

Table 2 TACE treatment characteristics and subsequent treatments

	cTACE (n = 174)		DEB TACE (n = 76)		p
TACE treatment	mean ± SD (range)		mean ± SD (range)
TACE sessions per patient (n)	4.00 ± 3.09 (1–18)		2.96 ± 1.79 (1–9)		<0.01
Total duration of TACE treatment (days)	217.4 ± 266.1		143.9 ± 171.5		0.01
Subsequent treatment	n^a	%	n^a	%
None	105	60.3	48	63.2	0.54
Crossover to other type of TACE					0.41
Yes	27	15.5	15	19.7
No	147	84.5	61	80.3
SIRT					0.09
Yes	11	6.3	1	1.3
No	163	93.7	75	98.7
Local ablation					0.18
Yes	12	6.9	2	2.6
No	162	93.1	74	97.4
Surgery					0.46
Yes	5	2.9	1	1.3
No	169	97.1	75	98.7
Sorafenib					0.77
Yes	25	14.4	12	15.8
No	149	85.6	64	84.2
Other systemic therapy					0.70
Yes	31	17.8	12	15.8
No	143	82.2	64	84.2
Patients receiving ≥2 treatments					1.00
Yes	16	9.2	7	9.2
No	158	90.8	69	90.8

TACE transarterial chemoembolization, SD standard deviation, SIRT selective internal radiotherapy
^aSome patients received ≥2 subsequent treatments; therefore, the total number of treatments is greater than the total number of patients

ISSN: 1471-2407